ubrogepant
ubrogepant is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including UBRELVY. Available dosage forms: tablet, powder.
Drug Details
- Generic Name
- ubrogepant
- Brand Names
- UBRELVY
- Application Number
- NDA211765
- Sponsor
- Allergan, Inc.
- NDC Codes
- 5
- Dosage Forms
- TABLET, POWDER
- Routes
- ORAL
- Active Ingredients
- UBROGEPANT
Indications and Usage
1 INDICATIONS AND USAGE UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. ( 1 )